Clofarabine label
In hospitalized patients. METHODS: The decision model, performed from the health care payer's perspective, evaluated a simulated cohort of 1000 hospitalized patients on general medical, surgical, urologic, and intensive care services requiring short-term urethral catheterization 2-10 days ; . We compared 2 catheterization strategies: silver alloy catheters and standard noncoated ; urinary catheters. Outcomes included the incidence of symptomatic UTI and bacteremia and direct medical costs. RESULTS: In the base-case analysis, use of silver-coated catheters led to a 47% relative decrease in the incidence of symptomatic UTI from 30 to 16 cases per 1000 patients number needed to treat 74 ; and a 44% relative decrease in the incidence of bacteremia from 4.5 to 2.5 cases per 1000 patients number needed to treat 500 ; compared with standard catheters. Use of silver alloy catheters resulted in estimated cost savings of .09 per patient compared with standard catheter use .87 vs .78 ; . In a multivariate sensitivity analysis using Monte Carlo simulation, silver-coated catheters provided clinical benefits over standard catheters in all cases and cost savings in 84% of cases. CONCLUSIONS: Using silver alloy catheters in hospitalized patients requiring short-term urinary catheterization reduces the incidence of symptomatic UTI and bacteremia, and is likely to produce cost savings compared with standard catheters. Saita T. et al. A highly sensitive ELISA for the quantification of polymyxin B sulfate in human serum. Biol Pharm Bull. 1999; 22 12 ; : 1257-61.p Abstract: A highly sensitive ELISA for the determination of polymyxin B sulfate PMB ; was developed which is capable of measuring as low as 32 pg ml.Anti-PMB antibody was obtained by immunizing rabbits with PMB conjugated with mercaptosuccinyl bovine serum albumin MS. BSA ; using N- gamma-maleimidobutyryloxy ; succinimide GMBS ; as a heterobifunctional coupling agent. An enzyme marker was similarly prepared by coupling PMB with horseradish peroxidase HRP ; employing GMBS.This ELISA showed very low reactivity with the PMB analogue, polymyxin E 0.05% ; . The values for PMB concentration detected by this assay were comparable with those detected by the bioassay. Moreover, the ELISA was about 10, 000 times more sensitive in detecting PMB at lower concentrations. Serum PMB concentration after the oral administration of a PMB tablet to human subjects was determined by the ELISA. PMB was rapidly absorbed from the gastrointestinal tract after the administration, then slowly decreased. These results indicate that the ELISA may be a valuable tool for studies of the pharmacokinetics and pharmacodynamics of the anti-endotoxin drug, PMB. Sakamoto M. et al. Sepsis associated with hematological malignancies: prophylaxis of Pseudomonas aeruginosa sepsis. Kansenshogaku Zasshi. 1996; 70 2 ; : 116-22.p Abstract: Underlying diseases, pathogenic bacteria, clinical background and outcome were studied during 91 febrile episodes complicated by sepsis in 55 patients with hematological malignancies, who had been admitted to our hospital Jikei University Kashiwa Hospital ; between January 1990 and December 1994. Particularly in patients with P. aeruginosa sepsis, we compared the prophylactic effect of ciprofloxacin CPFX ; alone with that of the combination of polymyxin B PL-B ; plus kanamycin KM ; .The major underlying diseases were acute myelocytic leukemia and malignant lymphoma, followed by myelodysplastic syndrome, acute lymphocytic leukemia and chronic myelocytic leukemia. Nearly two-thirds of the pathogenic microorganisms isolated were grampositive bacteria including coagulase-negative staphylococci and Staphylococcus aureus approximately one-quarter were gram-negative bacteria such as Pseudomonas aeruginosa ; , and the remainder were fungi.These microorganisms usually induced sepsis when granulocyte counts were decreased. Sepsis was a direct cause of death in about 60% of the patients and P. aeruginosa sepsis had the worst outcome. Oral administration of CPFX was more effective than PL-B plus KM in preventing P. aeruginosa sepsis.The difference in effectiveness might depend on the absorption profile of the drugs.
Clofarabine label
In addition, a fluoride molecule at the 2' position of the carbohydrate prevents phosphorylation of the glycosidic linkage, improving clofarabine bioavailability and preventing the release of the neurotoxic halogenated adenine moiety.
Fda approval for clofarabine - information from the fda about the approval of this drug and the clinical trials that led to the approval.
Chemo thing, which makes you feel like absolute shit. But the hardest part was missing school and being away from my friends. Most of the girls were worrying about which dress to wear to the formal, while I worrying about which wig I would wear to the formal. if I made it at all. While chemo fixed my body, it was the people at CanTeen that healed my mind and spirit. Having cancer is a surreal experience and being able to talk to people who've been there, done that, is an invaluable help. CanTeen was good to me, which is why I now good to them. Being on the CanTeen committee last year, I supported other cancer patients, their siblings and children and helped them realise that cancer isn't a death sentence. Shit happens and although your life is never the same after cancer, there are some unexpected perks. Tickets to Guns `n' Roses, a trip to the UK and Thredbo.
Clofarabine structure
Study included a dose-finding phase I portion in which 9 patients received doses of clofarabine below the single-agent MTD dose of 40 mg m day x 5 days. Second, patient selection may have played a role. Whereas in the combination study 28% patients with AML had primary refractory disease to initial induction, and an additional 44% had a first remission duration of less than 12 months, only 35% of the AML population in the single-agent phase II study had a first remission duration of less than 12 months or had primary refractory disease.
In summary, clofarabine is one of the few nucleoside analogues besides ara-C ; that has shown activity in adult AML as a single agent and at well-tolerated doses. Clofarabine triphosphate is accumulated and retained in leukemia blasts, resulting in a decline of leukemia cells, and making it an ideal candidate for biochemical modulation strategies. We have shown that clofarabine can be safely combined with ara-C, and that the combination has clinical activity. Evaluation of this combination strategy in older patients with newly diagnosed AML and high-risk MDS is currently ongoing. Further mechanism-based combinations of clofarabine with other active agents anthracyclines, alkylators ; are planned and clofibrate.
Do. And in New York I've met a Negro musician named Leadbelly who's a fantastic musician but nobody's recording him. They say he's not commercial. But I think this is American culture and it should be recorded. Down in the Library of Congress they record things and just put it on the shelf there and only a few people ever hear them. Well, Einstein says, "You're exactly right. Americans don't appreciate their culture. It'll be a Polish Jew like you who will do the job." And Mo Asch recorded Leadbelly. And I asked Mo years later how many copies did you sell. And he said the first year we sold one hundred copies. Well, sales picked up. The next year, Woody Guthrie came into town he recorded Woody. During World War II he found that no one was recording the songs of the Abraham Lincoln Battalion, the Americans that had volunteered to fight Franco in Spain, back in nineteen thirty seven. And I got a weekend pass from the army, and with three others, Bess Lomax Hawes, Tom Glazer and Butch Hawes, four of us. We rehearsed on Saturday and recorded in our fractured Spanish six songs of the Abraham Lincoln Battalion. And by gosh you know, they're still being sold. And when I went to Spain, guess what, I found they had, they were singing the same version of the song. Everyone sings a different version of songs. And I said, "How come you're singing the same exact version as I'm singing?" And they said, "We learned off your record." [END OF PART ONE -- MORE OF PETE SEEGER ON THE HISTORY OF THE BANJO, WRITING "HOW TO PLAY THE 5-STRING BANJO, " EARL SCRUGGS AND THE FOLK REVIVAL IN PART TWO].
Clofarabine and mds
| Clofarabine injectionFlexion-extension and radial-ulnar components of this torque controlled the horizontal and vertical position of a cursor on a screen. The monkey's task was to hold the cursor inside targets which appeared on the screen. One complete trial required the monkey to move the cursor from a central target to one of eight peripheral targets and hold for 1 second before returning to the center to receive a fruit sauce reward and clorazepate.
Calm-aid , carbacot , carbamazepine , carbamazepine extended release , carbatrol , carbetapentane , cardura , cardura xl , carduran , carteolol , cartrol , carvedilol , carvedilol extended release , cascor , catapres , catapres-tts-1 , catapres-tts-2 , catapres-tts-3 , celexa , celontin , cesamet , cetirizine , chem mart tramadol , chlo-amine , chlor-al rel , chlor-mal , chlor-phen , chlor-phenit , chlor-trimeton , chlor-trimeton allergy sr , chloral hydrate , chlordiazepoxide , chlorphen , chlorpheniramine , chlorpheniramine allergy ; , chlorpheniramine 24 hour extended release , chlorpheniramine extended release , chlorpromazine , chlorpromazine extended release , chlortan , citalopram , clofarabine , clolar , clomipramine , clonazepam , clonidine , clonidine topical , clopine , clorazepate , clorazepate extended release , clozapine , clozapine synthon , clozaril , codeine , codeine phosphate , codeine sulfate , codimal a , cogentin , compazine , compazine spansule , compoz nighttime sleep aid , compro , comtan , cophene b , coreg , coreg cr , corgard , cymbalta , dalgan , dalmane , dantrium , dantrium intravenous , dantrolene , dehydrated alcohol , demerol hcl , denzapine , depacon , depakene , depakote , depakote er , depakote sprinkles , depodur , deserpidine , desipramine , desyrel , desyrel dividose , dexmedetomidine , dezocine , di-phen , diastat , diastat acudial , diastat pediatric , diazepam , dihydrocodeine , dilantin , dilantin infatabs , dilantin kapseals , dilantin-125 , dilaudid , dilaudid-5 , dilaudid-hp , dimetane , dimetane extentab , dimetapp allergy , dimetapp allergy liquigel , diphedryl , diphen , diphen af , diphen cough , diphenadryl , diphendryl , diphenhist , diphenhydramine , diphenhydramine citrate , diphenhydramine tannate , diphenmax , diphenydramine quick melt , diphenyl , diphenylin , diprivan , diskets , diurese , divalproex sodium , divalproex sodium extended release , dizac , dolophine , doloral , doloral sirop , doral , doxadura , doxazosin , doxazosin extended release , doxepin , doxepin topical , doxylamine , dph , dromadol sr , dromadol xl , dronabinol , droperidol , duloxetine , duraclon , duragesic , duragesic-100 , duragesic-12 , duragesic-25 , duragesic-50 , duragesic-75 , duramorph pf , dytan , dytuss , echinacea , ed chlor-tan , ed chlorped , edecrin , edecrin sodium , effexor , effexor xr , efidac-24 chlorpheniramine , elavil , endep , endocodone , enduron , entacapone , epitol , eplerenone , equanil , equetro , escitalopram , eskalith , eskalith-cr , esmolol , estazolam , eszopiclone , eth-oxydose , ethacrynic acid , ethanol , ethosuximide , ethotoin , ethyl alcohol , fazaclo , felbamate , felbatol , fentanyl , fentanyl topical , fentora , flavoxate , fluoxetine , fluoxetine extended release , fluphenazine , fluphenazine decanoate , fluphenazine enanthate , fluphenazine hydrochloride , flurazepam , fluvoxamine , folex pfs , gabapentin , gabarone , gabitril , genahist , genrx tramadol , geodon , guanadrel , halazepam , halcion , haldol , haldol decanoate , haloperidol , haloperidol decanoate , harmonyl , histaject , hydramine , hydramine compound , hydramine cough syrup , hydrocodone , hydromorph contin , hydromorphone , hydromorphone extended release , hydrostat ir , hydroxyzine , hydroxyzine hydrochloride , hydroxyzine pamoate , hylorel , hypericum perforatum , hyrexin , hytrin , hyzine , imipramine , imipramine pamoate , inapsine , inderal , inderal la , infumorph , innopran xl , inspra , interferon beta-1a , interferon beta-1b , invega , ionsys , iopidine , isocarboxazid , j-tan , j-tan pd , kadian , kemadrin , keppra , kerlone , ketalar , ketamine , klonopin , klonopin wafer , labetalol , lamictal , lamictal blue , lamictal cd , lamictal green , lamictal orange , lamotrigine , larapam sr , largon , leflunomide , levatol , levetiracetam , levo-dromoran , levocetirizine , levomethadyl acetate , levorphanol , levrix , lexapro , librium , lioresal , lioresal intrathecal , lithium , lithium carbonate , lithium carbonate extended release , lithium citrate , lithobid , lithonate , lithotabs , lodrane 12 hour , lodrane 24 , lodrane xr , lopressor , lorazepam , loxapine , loxitane , loxitane c , loxitane im , ludiomil , luminal , lunesta , luvox , lyrica , m-eslon , m-oxy , o.
Where to buy Clofarabine
We also measured the T-, B-, and natural killer NK ; cell reconstitution by flow cytometry. Before transplantation, the mean numbers of CD3 , CD4 , and CD8 cells in group 1 were within normal ranges CD3 , 900-3700 L blood; CD4 , 550-2150 L blood; CD8 , 200-1400 L blood ; , whereas the mean values for these 3 populations in group 2 were below the normal ranges Table 3 ; . At the first month after AHSCT, the T-cell populations were dramatically decreased in both groups. The numbers in group 1, however, were higher than those in group 2 by a factor of 6 to times at this time point. The numbers had begun to increase in both groups at the second month. T-cell populations were not found to differ statistically during the first 8 months after AHSCT, although counts in group 1 were 2 to 8 times those in group 2. Until 8 months, all of the T-cell populations in both groups were below the normal range, with the exception of CD8 cell numbers in group 1 at months 6, 7, and 8. Prior to transplantation, the mean of CD4 CD8 ratio for group 1 was 2.8 times that of group 2 Table3 ; . During the first 3 months after AHSCT, the ratio was less than 1 in both groups. We observed and clove.
|
Using serum creatinine SC ; at 1 year rather than acute rejection episodes AREs ; makes sense as SC measures the damage to the kidney caused by AREs. We set out to prove that SC was a better surrogate marker than AREs through analysis of the relationships of both with long term outcomes. We compared the relationship between AREs within the first year post-transplant and SC levels recorded at one year as markers of patient and graft survival. Comprehensive data were available from 1978 to 2001 for 937 transplants in Cardiff. Survival estimates are reported using mean covariates using Kaplan-Meier and Cox proportional-hazards models. There were 352 37.6% ; females and 73 7.8% ; subjects had pre-existing diabetes DM ; . Median age at first graft was 42 years IQR 30-54 ; and median SC at one-year was 149 mmol.l-1 IQR 119 to 200 ; . In year-1, 283 30.3% ; subjects experienced one ARE; 149 15.9% ; two and 115 12.3% ; three or more. SC levels in those with no ARE versus those with at least one ARE were 134 mmol.l-1 and 166 mmol.l-1, respectively p 0.001 ; . Mean patient survival was 16.3 years for those with no ARE and 13.7 years in those with at least one ARE p 0.346 ; . Excluding patient deaths, mean graft survival was 15.3 years with no ARE versus 12.1 years with at least one ARE p 0.012 ; . After adjustment for age, sex, DM and SC levels, patient survival was not significantly associated with AREs. The relative hazard RH ; for graft survival excluding deaths ; with at least one ARE in year-1 was 1.36 95%CI 0.997 to 1.843; p 0.052 ; . The RH for graft survival including patient deaths was 1.45 CI 1.14 to 1.84; p 0.003 ; . After classifying AREs as 0, 1, 2, or 3 more episodes, there was no association with patient survival. After excluding deaths, there was a significant association between graft survival and those patients experiencing three or more AREs RH 1.63: CI 1.083 to 2.47; p 0.019 ; . There was an association with graft survival with one or two AREs in the year-1. After adjusting for age, sex and DM, SC was associated with patient survival for a 10 mmol.l-1 increase RH 1.001: CI 1.001 to 1.0142; p 0.001 ; . After excluding patient deaths, SC levels were found to be significantly associated with graft survival for a 10 mmol.l-1 increase RH 1.082: CI 1.053 to 1.131; p 0.001 ; . SC levels recorded at one-year post transplant are a more reliable predictor of patient and graft survival than are acute rejection episodes in year-1. The predictive value of AREs is usually lost in multivariate analysis.
Clofarabine clorar
United Plant Savers P.O. Box 98, East Barre, VT 05649 - plantsavers National Center for the Preservation of Medicinal Herbs 33560 Beech Grove Rd, Rutland, OH 45775 ncpmh Suggested reading: Sturdivant, Lee and Tim Blakely. 1999. Medicinal Herbs in the Garden, Field, and Marketplace. San Juan Naturals. Friday Harbor, WA. ISBN 0-9621635-7-0. Gladstar, Rosemary and Pamela Hirsch. 2000. Planting the Future; Saving our Medicinal Herbs. Healing Arts Press. Rochester, VT. ISBN 0-89281-894-8. Zo Gardner is the Program Coordinator of the Medicinal Plant Program in the Department of Plant and Soil Sciences at the University of Massachusetts. She is a former apprentice at National Center for Preservation of Medicinal Herbs in Rutland, OH, an organization that conducts research on the cultivation of native medicinal plants. She can be reached at ZoeEGardner hotmail or 12A Stockbridge Hall, University of Massachusetts, Amherst, MA 01003 and codeine.
1 0 2007 bookmarken drucken senden vorlesen schrift: bioenvision provides evoltra r ; clofarabine ; regulatory update bioenvision, inc nasdaq: bivn ; today announced an update on the status of its marketing authorization application to the european medicines evaluation agency emea ; to include a new indication for evoltra clofarabine ; for the treatment of acute myeloid leukaemia aml ; in elderly patients who have one or more of the following: adverse cytogenetics, secondary aml, 70 years old or significant co-morbidities and are therefore not considered suitable for intensive chemotherapy.
Complete chemical, biological, radiological defense cbrd ; fundamentals pqs locate and transit decontamination station cca stations locate casualty collection stations and deep shelter stations don and doff chemical protective ensemble change protective mask canister use the m-291 skin decon kit demonstrate self and buddy aid for nerve agent exposure identify cbr markers use m8 and m9 paper pass through cps air lock pressure lock decontaminate internal and external areas satisfactorily perform or simulate immediate actions for the following emergencies: nuclear attack, chemical attack, biological attack, nuclear radiation exposure, chemical agent exposure, and biological agent exposure and cogentin.
He also maintains a position on the clofarabine management team that is responsible for all drug development activities relating to that lead drug, and has been instrumental in the development and maintenance of our key relationships within the scientific research and medical communities, and those with our vendors, inventors, co-development partners and licensors
Dence, is not often seen among individuals entering treatment 911 ; . The lifetime rate was estimated to be between 4% and 8% in a large national study and in regularly drinking individuals residing near New York City 7, 9, 12 ; . The lifetime prevalence of alcohol abuse is likely to be higher among individuals with family histories of alcoholism, although not all studies agree. A rate of approximately 15% was reported for 30-year-old men taking part in a prospective study of matched pairs of individuals with and without family histories of alcohol use disorders 9, 12, 13 ; . Most studies report higher lifetime rates of alcohol abuse among men than among women 7, 14, 15 ; . Data are also available on the relationship between a diagnosis of alcohol abuse and the future risk for developing alcohol dependence. The follow-up of a group of more than 450 30-year-old men in San Diego revealed that only 11% of those with a lifetime diagnosis of alcohol abuse went on to develop alcohol dependence during the subsequent 5 years 16, 17 ; . Another general population study indicated a 1-year rate of 6% for conversion of alcohol abuse to alcohol dependence 18 ; . However, the rate of future alcohol dependence for those with abuse is not always higher than for comparison subjects with no baseline alcohol use disorder 9, 17 ; . Individuals with alcohol abuse are likely to continue to have alcohol-related problems over time. In the San Diego Prospective Study, almost 50% of men with alcohol abuse at age 30 years continued to meet the DSM-IV criteria for that disorder over the next 5 years, a rate of problems that was significantly greater than the 15% risk for abuse onset for those with no diagnosis at baseline and less than the 63% rate for repetitive problems for those with alcohol dependence 16 ; . A 1-year follow-up of another group of subjects reported that 27% of those with alcohol abuse still maintained that diagnosis 1 year later, a rate that was six times higher than for comparison subjects without alcohol abuse at baseline 9, 18 ; . Data from the six-center Collaborative Study on the Genetics of Alcoholism indicated that 55% of individuals with a lifetime diagnosis of alcohol abuse at initial evaluation continued to meet the criteria for abuse during a 5-year follow-up 17 ; . The coherence and distinctive nature of the criteria for alcohol abuse have been supported by most factor analytic studies that included both abuse and dependence items 1922 ; . In addition, the clinical characteristics of individuals with alcohol abuse have been compared to those with no diagnosis or to those with alcohol dependence; typically the parameters relating to abuse tended to fall midway between the two extremes 3, 7, 23 ; . These parameters include indicators of the usual quantity and frequency of drinking, histories of having received prior treatment for alcohol use disorders, and the rates of alcohol-related problems e.g., blackouts ; that are not part of the alcohol abuse criteria and cognex.
Order generic Clofarabine online
Treatment paradigm. Steven Gore, MD, of the Sidney Kimmel Cancer Center provides an opening discussion by summarizing therapeutic goals framed by prognostic features and expectations for survival. Second, Richard Stone, MD, of the Dana-Farber Cancer Center discusses currently available approaches and novel therapeutics on the horizon. Third, Lewis Silverman, MD, of Mount Sinai Medical Center and the lead investigator for the Cancer and Lung Group B CALGB ; cooperative group study in MDS, provides an overview of the pharmacology and results of clinical trials investigating methyltransferase inhibitors and azacitidine. Finally, I outline a new treatment algorithm for MDS built upon the incorporation of active therapy that represents consensus recommendations of thought leaders on this disease. MDS is no longer an "orphan disease" without effective treatment options. Through this supplement, the contributors aspire to raise awareness and invite discussion that will lead to new and effective additions to the treatment paradigm. Alan List, MD and clofarabine
2.4.2 Cancer of the oral cavity 2.4.2.1 Evaluations and colace.
Allowing increased production and accumulation of ara-CTP. That there can, indeed, be biochemical synergy between ara-CTP and clofarabine has been demonstrated in K562 cells in vitro. In this model system, 3-hr pretreatment with clofarabine followed by incubation with ara-C, led to a 2-fold increase in the concentration of ara-CTP relative to cells incubated with ara-C alone. Such biochemical modulation strategies for increasing intracellular nucleotide analogue concentrations has been demonstrated clinically in combination strategies of ara-C with either fludarabine or cladribine in adult acute leukemias.
Was a wide inter-individual variation in estimated IC50 Tables 2 and 3, Figures 1 and 2 ; . Median IC50 was 37 and 60.5 nguml for patients and controls, respectively range 20.5 to ; 250 and 35 to ; 250 nguml, interquartile range 34 to 88 and 39 to 215 nguml in patients and controls respectively ; . There was a suggestion that patients were more sensitive than controls in that median IC50 was lower in this group, however this was not statistically significant Wilcoxon rank sum test Ps0.09 ; . The reproducibility of the assay was assessed in three patients and two controls at intervals of 9 months to 2 years after initial assay. While similar values were observed for per cent inhibition and IC50, per cent lysis was less reproducible Tables 2 and 3 and colesevelam.
546 [p 1021] Kubic C, Adams R. Occlusion of the basilar artery: a clinical and pathologic study. Brain 69: 73-121, 1946 and clofibrate.
Clofarabine drug
In the event of such payment, the decision of management to transfer manufacturing and marketing rights for clofarabine and products in the usa and canada under this section, via the grant of an exclusive license to ilex, shall be accelerated to the date of payment and the conditions for completion of the co-development program set forth herein, including the milestone events in section 2 hereof shall be deemed satisfied for purposes of, but only for the purposes of, granting of the exclusive license to ilex as set forth in this section and colestipol.
Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003; 237: 171-179 Bartolozzi C, Lencioni R. Ethanol injection for the treatment of hepatic tumours. Eur Radiol 1996; 6: 682-696 Wakai T, Shirai Y, Suda T, Yokoyama N, Sakata J, Cruz PV, Kawai H, Matsuda Y, Watanabe M, Aoyagi Y, Hatakeyama K. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma or 4 cm. World J Gastroenterol 2006; 12: 546-552 Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62 Suppl 1: 64-68 Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006; 12: 828-829 Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, Tsuchihashi T, Saigenji K. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR J Roentgenol 2007; 188: 480-488 Schindera ST, Nelson RC, DeLong DM, Clary B. Intrahepatic tumor recurrence after partial hepatectomy: value of percutaneous radiofrequency ablation. J Vasc Interv Radiol 2006; 17: 1631-1637 Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, Lee KW, Joh JW. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and wellpreserved hepatic function. J Clin Gastroenterol 2005; 39: 247-252 Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis 2001; 5: 161-173 Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004; 240: 102-107 Nakahara H, Itamoto T, Katayama K, Ohdan H, Hino H, Ochi M, Tashiro H, Asahara T. Indication of hepatectomy for cirrhotic patients with hepatocellular carcinoma classified as Child-Pugh class B. World J Surg 2005; 29: 734-738 Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004; 10: S39-S45 Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg 2006; 244: 265-273 Liu YM, Qin H, Wang CB, Fang XH, Ma QY. Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer. World J Gastroenterol 2006; 12: 5060-5063 Jiao LR, Hansen PD, Havlik R, Mitry RR, Pignatelli M, Habib N. Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. J Surg 1999; 177: 303-306 S- Editor Tsui TY L- Editor Roberts SE E- Editor Yin DH.
Clofarabine 2005
Clofarabine what is
Cerebral palsy learning disabilities, antidepressants nursing, intercellular matrix of bone tissue, anxiety disorder online test and benign joint hypermobility disorder. Aesculapius medical press, atria of stamford, antiseptic germicide and estrogens in shampoo or ear piercing bleeding.
Clofarabine more for_patients
Clofarbaine, clofarabkne, clofxrabine, clofarabinw, clofrabine, clofsrabine, xlofarabine, clofarabime, clofarabins, clofarabin3, coofarabine, cofarabine, clofaravine, clofarqbine, cloofarabine, clofarablne, clofarrabine, clfarabine, clofa5abine, clofadabine.
Clofarabine wiki
Clofarabine label, clofarabine structure, clofarabine and mds, clofarabine injection and where to buy clofarabine. Clofarabine clorar, order generic clofarabine online, clofarabine drug and clofarabine 2005 or clofarabine what is.
|
